Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor...
36 KB (3,447 words) - 05:37, 9 August 2024
effectiveness of everolimus in carcinoid tumors have not been established. sunitinib (Sutent) is labeled for treatment of progressive, well-differentiated...
28 KB (2,476 words) - 01:37, 1 October 2024
(NSCLC). Sunitinib is an oral drug that inhibits the phosphorylation of all the VEGF receptors, PDGFR-ß, KIT FLT3, CSF1R and GDNF. Sunitinib is used in...
51 KB (4,735 words) - 08:15, 2 January 2024
cytokine therapy (IL-2, interferon), kinase inhibitors (temsirolimus, sunitinib, sorafenib, pazopanib) and anti-angiogenic therapies (bevacizumab). "Clear...
3 KB (333 words) - 01:07, 3 December 2023
shut down in 2003, after developing the pioneering kinase inhibitor drug sunitinib (Sutent). Sugen was founded in 1991 in Redwood City, California, by veteran...
8 KB (823 words) - 17:00, 26 September 2024
small molecules that inhibit the tyrosine kinases stimulated by VEGF: sunitinib, sorafenib, axitinib, and pazopanib (some of these therapies target VEGF...
14 KB (1,671 words) - 23:17, 4 September 2024
inhibitor that is effective both as a senolytic and as therapy for CML. Sunitinib, an inhibitor of the receptors for FGF, PDGF and VEGF is also based on...
10 KB (1,179 words) - 18:31, 8 August 2024
tyrosine kinase inhibitor sunitinib (marketed as Sutent) can be considered.: 26 and 31 The effectiveness of imatinib and sunitinib depend on the genotype...
43 KB (4,502 words) - 18:59, 16 July 2024
Retrieved 20 July 2023. "A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma". www.clinicaltrials.gov. Retrieved...
18 KB (1,467 words) - 23:44, 20 August 2024
phosphate. It was developed by SUGEN as SU11654, a sister compound to sunitinib, which was later approved for human therapies. Toceranib is a tyrosine...
7 KB (374 words) - 00:31, 1 July 2024
randomized study of zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced or metastatic non-clear cell RCC (nccRCC). Sharma...
5 KB (188 words) - 12:33, 5 September 2024
Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...
42 KB (3,935 words) - 04:01, 30 April 2024
MedlinePlus. Clinical trial number NCT01835158 for "Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced...
21 KB (1,640 words) - 06:51, 18 September 2024
Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...
92 KB (8,729 words) - 10:30, 16 October 2024
Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...
31 KB (3,430 words) - 05:24, 28 August 2024
erlotinib has replaced gefitinib in this setting. Sorafenib (Nexavar) Sunitinib (Sutent) Dasatinib (Sprycel) Lapatinib (Tykerb) Nilotinib (Tasigna) Bosutinib...
20 KB (2,234 words) - 01:21, 22 July 2024
(OSM) Thymic stromal lymphopoietin (TSLP) Additional cytokine receptor modulators: Emfilermin Lestaurtinib Midostaurin Quizartinib Sorafenib Sunitinib...
35 KB (3,270 words) - 15:33, 10 October 2024
stabilizers, amiodarone, interferon alpha, tyrosine kinase inhibitors such as sunitinib Central hypothyroidism Lesions compressing the pituitary (pituitary adenoma...
79 KB (8,159 words) - 13:33, 14 October 2024
Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...
11 KB (934 words) - 14:21, 19 September 2024
Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...
68 KB (5,999 words) - 20:41, 31 August 2024
inhibitors specific to such domains as CC, Y177, and Rho (such as imatinib and sunitinib) are important drugs against a variety of cancers including CML, renal...
29 KB (3,538 words) - 15:01, 5 December 2023
cancer therapies, especially the tyrosine kinase inhibitors sorafenib and sunitinib, have also been associated with a high incidence of acral erythema. However...
16 KB (1,639 words) - 14:02, 28 August 2024
removal and is causing symptoms, targeted therapy with everolimus or sunitinib can reduce symptoms and slow progression of the disease. Standard cytotoxic...
122 KB (12,861 words) - 08:19, 16 October 2024
Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...
149 KB (15,702 words) - 00:28, 14 October 2024
Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...
22 KB (1,993 words) - 23:37, 23 March 2024
trial number NCT02231749 for "Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate...
46 KB (4,813 words) - 05:06, 15 October 2024
treatment for patients with advanced kidney cancer after failure of either sunitinib or sorafenib" (Press release). Novartis. 30 March 2009. Archived from...
27 KB (2,534 words) - 20:49, 4 October 2024
vinblastine, vincristine, vindesine, imatinib, irinotecan, sorafenib, sunitinib, vemurafenib, temsirolimus, anastrozole, gefitinib; azole antifungals:...
80 KB (7,794 words) - 21:26, 15 July 2024
approved within the past ten years. These treatments are: Nivolumab Axitinib Sunitinib Cabozantinib Everolimus Lenvatinib Pazopanib Bevacizumab Sorafenib Tivozanib...
100 KB (10,959 words) - 19:54, 11 October 2024
Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...
121 KB (13,799 words) - 17:37, 8 October 2024